Shanghai Henlius Biotech Inc. has inked a deal to acquire greater China rights for two cancer-focused bifunctional sialidase programs from Palleon Pharmaceuticals Inc. In return, Palleon will receive an unspecified up-front payment and is eligible for up to $196.5 million in milestone payments.
Sunshine Guojian Pharmaceutical Co. Ltd. has granted Xiling Lab Pharmaceutical Co. Ltd. global rights to develop and commercialize the trastuzumab biosimilar Cipterbin (inetetamab) for antibody-drug conjugates (ADC) in a ¥1.03 billion (US$153 million) deal.
Pfizer Inc. and Biontech SE have signed a deal with the U.S. government to supply up to 300 million doses of COVID-19 vaccines in a deal worth more than $3.2 billion. Depending on the U.S. FDA, the vaccine doses fulfilling the order may include the companies’ omicron-adapted candidate, which they reported June 25 demonstrated a high immune response against the omicron BA.1 subvariant of SARS-CoV-2, when given as a fourth booster.
London-based Invox Pharma Ltd. has announced plans to acquire F-star Therapeutics Inc. for $161 million to build up the presence of its parent company, Sino Biopharm Ltd., outside of China.
Armed with compelling phase IIb data and with two phase III trials underway, Newamsterdam Pharma BV has sealed a European commercialization deal worth more than €1 billion (US$1.6 billion) with Menarini Group for its cholesterol lowering drug, obicetrapib.
Astellas Pharma Inc. and Sutro Biopharma Inc. signed an exclusive global licensing deal under which Sutro will develop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets for Astellas.
After its $247 million acquisition of Epizyme Inc., Ipsen SA will continue to shop for M&A prospects, said Ipsen CEO David Loew, noting that “the [company’s] firepower has not been absorbed in a significant fashion by this deal,” and the firm might undertake a larger transaction next time in oncology, rare diseases, or neurology.
Pfizer Australia Holdings Pty Ltd. has revised its offer to acquire digital health company Resapp Health Ltd. after results from an independent data confirmation study of its COVID-19 algorithm failed to meet Pfizer’s required sensitivity and specificity results.
Galapagos NV is making a decisive shift away from its small-molecule roots, sealing the simultaneous acquisition of CAR T-cell therapy specialist Cellpoint BV and fully-human antibody company Aboundbio Inc. The Cellpoint deal is by far the largest, with Galapagos paying €125 million (US$132 million) cash up front, with a further €100 million to come in milestones. The price for Aboundbio of Pittsburgh, is $14 million.
As fellow gene editing firm Crispr Therapeutics AG hosted an innovation day in which it confirmed plans for regulatory filings by year-end for an ex vivo gene editing therapy in sickle cell disease and beta-thalassemia, Precision Biosciences Inc. announced plans to develop an in vivo gene editing approach through a collaboration with Novartis AG that brings Precision an initial $75 million with up to $1.4 billion in potential milestones.
RSS
